Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19
Description: Types, frequencies, and severities of adverse events and their relationships to COVI-GUARD
Measure: Incidence of adverse events (safety) Time: Randomization through study completion through Day 60Description: Types, frequencies, and severities of treatment-emergent adverse events and their relationships to COVI-GUARD
Measure: Incidence of treatment-emergent adverse events (safety) Time: Randomization through study completion through Day 60Description: Types, frequencies, and severities of serious adverse events and their relationships to COVI-GUARD
Measure: Incidence of serious adverse events (safety) Time: Randomization through study completion through Day 60Description: All-cause mortality at 29 and 60 days
Measure: All-cause mortality at 29 and 60 days Time: Randomization through Day 29 and Day 60Description: Dose-limiting toxicities, particularly presence of acute or delayed hypersensitivity reactions
Measure: Incidence of dose-limiting toxicities (safety) Time: Randomization through study completion through Day 60Description: Clinically meaningful laboratory abnormalities
Measure: Incidence of laboratory abnormalities (safety) Time: Randomization through study completion through Day 60Description: Plasma samples and salivary samples are taken to correlate viral load with nasopharyngeal testing at various timepoints; stool or rectal swab samples are taken if possible for additional virologic assessments
Measure: SARS-CoV-2 viral load as assessed using various sample types Time: Randomization through study completion through Day 60Description: Time from onset of COVID-19 symptoms to hospitalization and to treatment on Day 1, and if applicable, time to ICU admission, discharge from ICU and discharge from hospital
Measure: Time to hospitalization, treatment, ICU admission, and discharge from ICU and/or hospital Time: Randomization up to study completion through Day 60Description: Presence and levels of anti-drug antibodies (ADA) directed to COVI-GUARD
Measure: Anti-drug antibodies Time: Randomization through study completion through Day 60Description: Levels of cytokines including EGF, IFNγ, IL-1β, IL-6, IL-8, IL-10, and TNFα
Measure: Cytokine levels Time: Randomization through study completion through Day 60Description: Area under the serum concentration-time curve (AUC) of COVI-GUARD
Measure: AUC of COVI-GUARD (PK) Time: Randomization through study completion through Day 60Description: Maximum observed serum concentration (Cmax) of COVI-GUARD
Measure: Cmax of COVI-GUARD (PK) Time: Randomization through study completion through Day 60Description: Apparent serum terminal elimination half life (t½) of COVI-GUARD
Measure: t½ of COVI-GUARD (PK) Time: Randomization through study completion through Day 60Description: Time to Cmax (Tmax) of COVI-GUARD
Measure: Tmax of COVI-GUARD (PK) Time: Randomization through study completion through Day 60Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports